Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Conventional Therapy at Different Periods: A Meta-Analysis of Randomized Controlled Trials
المؤلفون المشاركون
Huang, Jing
Xiong, Shuyuan
Ding, Shenglan
Cheng, Qingfeng
Liu, Zhiping
المصدر
العدد
المجلد 2020، العدد 2020 (31 ديسمبر/كانون الأول 2020)، ص ص. 1-13، 13ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2020-12-14
دولة النشر
مصر
عدد الصفحات
13
التخصصات الرئيسية
الملخص EN
Aims.
To assess the safety of ertugliflozin in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with conventional therapy at different periods.
Methods.
We searched PubMed, Embase, and The Cochrane Library from inception to September 23, 2020.
A total of six studies involving 4120 patients were included.
Results.
Compared with the control group, 15 mg and 5 mg of ertugliflozin were associated with higher risks of genital mycotic infections (GMIs) at 26 weeks (p<0.0001 and p<0.0001, respectively), 52 weeks (p<0.00001 and p<0.0001, respectively), and 104 weeks (p<0.00001 and p<0.0001, respectively).
Moreover, females had a higher risk of GMIs than males in the 15 mg group at 26 weeks (p=0.0008), 52 weeks (p<0.0001), and 104 weeks (p=0.02).
At 104 weeks, 15 mg and 5 mg of ertugliflozin showed beneficial effects on symptomatic hypoglycemia (p<0.00001 and p=0.004, respectively) compared with the effects observed in the control group.
Compared with the control group, 15 mg and 5 mg of ertugliflozin were associated with higher risks of drug-related adverse events at 26 weeks (p=0.002 and p=0.002, respectively); 15 mg of ertugliflozin was associated with a higher risk of discontinuation related to adverse events at 104 weeks (p=0.03).
No significant differences were found in the remaining safety outcomes.
Conclusion.
This meta-analysis of randomized controlled trials indicates that ertugliflozin is tolerated by T2DM, but the risk of GMIs is noteworthy, especially among females in the high-dose group.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Huang, Jing& Xiong, Shuyuan& Ding, Shenglan& Cheng, Qingfeng& Liu, Zhiping. 2020. Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Conventional Therapy at Different Periods: A Meta-Analysis of Randomized Controlled Trials. Journal of Diabetes Research،Vol. 2020, no. 2020, pp.1-13.
https://search.emarefa.net/detail/BIM-1183589
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Huang, Jing…[et al.]. Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Conventional Therapy at Different Periods: A Meta-Analysis of Randomized Controlled Trials. Journal of Diabetes Research No. 2020 (2020), pp.1-13.
https://search.emarefa.net/detail/BIM-1183589
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Huang, Jing& Xiong, Shuyuan& Ding, Shenglan& Cheng, Qingfeng& Liu, Zhiping. Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Conventional Therapy at Different Periods: A Meta-Analysis of Randomized Controlled Trials. Journal of Diabetes Research. 2020. Vol. 2020, no. 2020, pp.1-13.
https://search.emarefa.net/detail/BIM-1183589
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1183589
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر